NCT05054530View on ClinicalTrials.gov

Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

November 17, 2023

Study Completion Date

November 17, 2023

Conditions

Overweight and Obesity

Interventions

DRUG

GMA106 Injection

GMA106 solution for injection. Subjects in each cohort will receive a single injection of GMA106 or matching placebo under fasting conditions and at the following target dose levels.

DRUG

GMA106 Matching Placebo

Matching Placebo for GMA106

Trial Locations (1)

5000

CMAX Clinical Research, Adelaide

All Listed Sponsors

lead

Gmax Biopharm Australia Pty Ltd.

INDUSTRY

NCT05054530 - Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106 | Biotech Hunter | Biotech Hunter